IPSC vs. PGEN, TNGX, TRVI, BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, and ITOS
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Precigen (PGEN), Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Century Therapeutics vs.
Century Therapeutics (NASDAQ:IPSC) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
In the previous week, Precigen had 5 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Precigen and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.33 beat Precigen's score of 0.45 indicating that Century Therapeutics is being referred to more favorably in the media.
Precigen has a net margin of -3,521.68% compared to Century Therapeutics' net margin of -4,837.73%. Century Therapeutics' return on equity of -61.66% beat Precigen's return on equity.
Precigen received 400 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 67.34% of users gave Precigen an outperform vote while only 66.04% of users gave Century Therapeutics an outperform vote.
Century Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
Century Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 999.75%. Precigen has a consensus target price of $6.33, indicating a potential upside of 470.57%. Given Century Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than Precigen.
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 6.8% of Century Therapeutics shares are held by insiders. Comparatively, 44.9% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Precigen has higher revenue and earnings than Century Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Century Therapeutics and Precigen tied by winning 9 of the 18 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:IPSC) was last updated on 1/21/2025 by MarketBeat.com Staff
Free IPSC Stock Alerts